The total return over the past 12 months is +9.69% vs. +16.94% for the S&P 500. So far it's up +19.42% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +9.69% | +32.59% | +3.75% | (17.34%) | N/A | N/A |
| Total Return CAGR | +9.69% | +32.59% | +3.75% | (17.34%) | N/A | N/A |
| Revenue CAGR | +119.40% | +100.64% | +36.81% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | +22.91% | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Zevra Therapeutics, Inc. (ZVRA)
| Year | Start price | End price | ZVRA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $8.96 | $10.70 | +19.42% | +14.51% | +4.91% |
| 2025 | $8.34 | $8.96 | +7.43% | +17.72% | (10.29%) |
| 2024 | $6.55 | $8.34 | +27.33% | +24.89% | +2.44% |
| 2023 | $4.59 | $6.55 | +42.70% | +26.19% | +16.51% |
| 2022 | $8.71 | $4.59 | (47.30%) | (18.17%) | (29.13%) |
| 2021 | $11.20 | $8.71 | (22.23%) | +28.74% | (50.97%) |
| 2020 | $6.06 | $11.20 | +84.70% | +18.37% | +66.33% |
| 2019 | $28.48 | $6.06 | (78.71%) | +31.22% | (109.93%) |
| 2018 | $64.80 | $28.48 | (56.05%) | (4.56%) | (51.49%) |
| 2017 | $47.20 | $64.80 | +37.29% | +21.70% | +15.59% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
